Sadly, some of the strongest characters that stand out in the books didn't make it into any of the Harry Potter movies.

Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...

Harry Potter introduced viewers to a world of wizards, spells, and fantastical creatures. Based on a book series of the same ...

More than 2,800 Texans are getting abortion pills through the mail from out-of-state every month, prompting a lawsuit and ...

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing ...

For branded drugmakers, the development of a pharmaceutical product approved by the Food and Drug Administration (FDA) all ...

As India marks a decade of its Act East Policy, Odisha is a vital hub, with its grand shoreline, foundational ports, and its historic maritime ties across southeast Asia, to unlock opportunities and ...